Key result
The renin angiotensin system plays an important role in coronary artery bypass graft performance, suggesting potential benefits of AT1-receptor antagonists over enzyme inhibitors to prevent graft disease.
The existence of a dual enzyme pathway for angiotensin II formation in bypass grafts suggests that AT1-receptor antagonists may be more effective than ACE inhibitors in preventing vein graft disease.
Answers are grounded in this paper and cite their sources.
May favor ARBs over ACEIs for CABG graft protection; leaves open randomized confirmation of clinical outcomes.
The renin angiotensin system is implicated in the development of vein graft disease after coronary artery bypass surgery. Components of this system have been shown to play important roles in determining the short-term and long-term performance of coronary artery bypass grafts. Significant differences exist in the commonly used arterial and venous grafts in angiotensin converting enzyme activity and angiotensin responses. The existence of a dual enzyme pathway in angiotensin II formation has also been demonstrated. Such findings have implications for the use of AT1-receptor antagonists over enzyme inhibitors to improve graft performance and prevent the development of coronary artery bypass graft disease.
No takes yet. Share an insight, caveat, or question.
Borland et al. (2000) conducted a review in Vein graft disease after coronary artery bypass surgery. AT1-receptor antagonists vs. Enzyme inhibitors was evaluated. The renin angiotensin system plays an important role in coronary artery bypass graft performance, suggesting potential benefits of AT1-receptor antagonists over enzyme inhibitors to prevent graft disease.
Synapse has enriched 10 related papers. Consider them for comparative context: